The most common mechanism of BRAF activation in thyroid cancer involves a point mutation that comprises a substitution of thymine to adenine at nucleotide position 1799, which results in replacement of a valine-to-glutamate at residue 600 (Val600Glu) [64]. This evidence concerns the gene BRAF and thyroid gland carcinoma.